

Re-purposing Ac/Ds transgenic system for CRISPR/dCas9 modulation of enhancers and non-coding RNAs in zebrafish

Vanessa Chong-Morrison^{1,3}, Filipa C. Simões^{1,2}, Upeka Senanayake¹, Dervla S. Carroll¹, Paul R. Riley² and Tatjana Sauka-Spengler^{1,*}

¹University of Oxford, Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, Oxford OX3 9DS, United Kingdom

²University of Oxford, Department of Physiology, Anatomy and Genetics, Oxford OX1 3PT, United Kingdom

³Current address: University College London, Department of Cell & Developmental Biology, London WC1E 6BT, United Kingdom

*Corresponding author: tatjana.sauka-spengler@imm.ox.ac.uk

Keywords: zebrafish, maize, Ac/Ds, CRISPR, enhancer, non-coding

Running title: Ac/Ds CRISPR/dCas9 in zebrafish

Summary statement

15

We adapted the Ac/Ds transposition system, which enables continuous expression of guide RNAs for CRISPR/dCas9 perturbation, to examine the function of non-coding RNAs and enhancer elements in zebrafish.

16

17

18

Abstract

19

Due to its genetic amenability coupled with recent advances in genome editing, the zebrafish serves as an excellent model to examine the function of both coding and non-coding elements. Recently, the non-coding genome has gained prominence due to its critical role in development and disease. Here, we have re-purposed the Ac/Ds maize transposition system to reliably screen and efficiently characterise zebrafish enhancers, with or without germline propagation. We further utilised the system to stably express guide RNAs in microinjected embryos enabling tissue-specific CRISPR/dCas9-interference (CRISPR*i*) knockdown of lncRNA and enhancer activity without disrupting the underlying genetic sequence. Our study highlights the utility of Ac/Ds transposition for transient epigenome modulation of non-coding elements in zebrafish.

20

21

22

23

24

25

26

27

28

Introduction

The non-coding genome has risen to prominence in recent years following successive studies highlighting its numerous roles in development and disease (Krijger and de Laat, 2016, Engreitz et al., 2016). The genome is populated by *cis*-regulatory elements called enhancers, which are active in a tissue-specific fashion (Rickels and Shilatifard, 2018) and probing their functional relevance requires inactivation in specific cell types and at distinct times. This is particularly important for key developmental regulators often deployed in well-defined spatiotemporal sequences, and thus likely to employ specific enhancers for such activity. Long non-coding RNAs, or lncRNAs, are defined as transcripts >200bp with no known protein product (Quinn and Chang, 2015). Unlike in the case of their protein-coding counterparts, functional studies to dissect lncRNA function can be challenging due to limiting factors such as their under-characterisation, low expression levels, short transcript length and rapid degradation. Furthermore, antisense lncRNAs that overlap protein-coding loci but are transcribed on the opposite strand are often found within important developmental loci (Bassett et al., 2014). Uncoupling their function from that of their cognate genes represents a major obstacle in the experimental design of relevant knockout studies.

In vitro methods for interrogation of non-coding RNAs and enhancers are useful but may not recapitulate results obtained from *in vivo* transgenic/knockout models, which, on the other hand, are often time-consuming. In this study, we have sought to bridge this gap by developing an efficient and flexible molecular toolkit to functionally assay non-coding elements in the zebrafish using transient and quantifiable *in vivo* approaches. The toolkit was based on re-purposing the maize transposon system first identified by Barbara McClintock in the late 1940s (McClintock, 1950). Molecular characterisation of the system led to identification of the components required for transposition to occur - two Ds (Dissociation) genetic elements and an Ac (Activator) transposase (Fedoroff et al., 1983). Buoyed by this important finding, Ac/Ds elements were employed to facilitate the integration of a reporter construct into the zebrafish genome with high efficiency, leading to remarkable germline transmission rates (Emelyanov et al., 2006). This approach was the integration method of choice used to generate transgenic

zebrafish lines for the chemical-inducible LexPR transactivation system (Emelyanov and Parinov, 2008, Kenyon et al., 2018), as well as for a systematic mutagenesis gene-trapping screen (Quach et al., 2015). While these studies demonstrated the utility of Ac/Ds as an efficient method for propagation of transgenes through the germline, they overlooked its strong potential for transient expression of DNA elements in F₀ embryos, which is a current limitation of the zebrafish model. Several other genome integration methods currently exist in vertebrates (Kawakami, 2007, Vrljicak et al., 2016). In particular in the zebrafish, Tol2-mediated genomic transposition is an established approach for somatic and germline integration of DNA constructs and is almost always the method-of-choice for generating transgenic reporter lines. For transient DNA integration experiments, however, Tol2-mediated transposition often produces variable results with a high rate of F₀ embryos displaying non-specific background and/or mosaic expression. The analysis of exogenous gene expression and testing of enhancer/reporter activity therefore often relies on the generation of F₁ offspring carrying relevant constructs. In this study, we expanded the use of Ac/Ds-mediated integration in zebrafish to test and validate putative *cis*-regulatory elements in transient, as an alternative to the Tol2-integration-based approach. This redirects the focus of previous zebrafish Ac/Ds-integration studies from germline propagation efficiency to characterisation of its utility for somatic integration-based experiments.

To efficiently probe non-coding element function in F₀ embryos in zebrafish, we have used tissue-specific epigenome engineering. Other knockdown approaches in injected F₀ zebrafish embryos currently exist, such as morpholino-mediated obstruction of protein synthesis or RNA-splicing, or somatic gene editing using TALENs or CRISPR/Cas9. However, these approaches lack spatiotemporal specificity and, as a result, render it difficult to distinguish between a cell-specific phenotype and secondary effects resulting from ubiquitous knockdown of the gene-of-interest. CRISPR/dCas9-based interference (CRISPR*i*) utilises nuclease-deficient Cas9 (dCas9) fused to transcriptional regulator domains which are targeted to specific genomic regions using “guide RNAs” (sgRNAs). To inhibit transcription, dCas9 can be targeted to transcription start sites (TSS) of genes to inhibit RNA Polymerase II by steric hindrance (Qi et al., 2013), or fused to effector domains such as Kruppel-associated box (KRAB) (Gilbert

et al., 2013) or four concatenated mSin3 repressive domains (SID4x) (Koneremann et al., 2013) 86
to induce chromatin changes inhibitive of transcription. Crucially, as CRISPR*i* complexes are 87
directed to the TSS of target genes, this allows the perturbation of gene expression without 88
modifying the endogenous locus sequence, making it a well-suited tool to study the function of 89
non-coding genes (Thakore et al., 2015, Koneremann et al., 2015, Liu et al., 2016, Williams et al., 90
2018). Similarly, ectopic activation of genes can be achieved by CRISPR*a* in specific cell types 91
using the VP64 activator domain (Mali et al., 2013). The caveat to using these approaches in 92
the zebrafish embryo is the need for extended expression of sgRNAs, which is limited by the 93
current gold-standard of injecting *in vitro*-transcribed sgRNAs. In the absence of Cas9 protein, 94
uncapped and non-polyadenylated sgRNAs degrade quickly (Mir et al., 2018). Therefore such 95
experiments can only be performed at the 1-cell stage and either have to be analysed during the 96
first 24-48 hours of development or sgRNA expression needs to be propagated to the germline. 97
Here, in addition to building zebrafish BAC transgenic lines expressing CRISPR*i/a* effectors 98
dCas9-SID4x and dCas9-VP64 in a tissue-specific fashion, we also generated and employed 99
Ac/Ds-integrated DNA constructs to deliver small guide RNAs constitutively in order to 100
transiently modulate the activity of non-coding elements in transgenic F₀ embryos *in vivo*. 101

Our Ac/Ds toolkit broadens the potential of the zebrafish embryo for rapid studies of 102
non-coding genomic elements. By harnessing its reliability and efficiency for somatic 103
integration, the toolkit can be robustly used either in transient and/or to complement 104
transgenic-based methods. 105

Results and Discussion 106


Ac/Ds transposition is more effective than Tol2 for transient integration of 107 transgenes in F₀ zebrafish embryos. 108

As a first step in re-purposing the maize Ac/Ds transposition system for zebrafish, we generated 109
a new enhancer/reporter construct (pVC-Ds-E1b:eGFP-Ds) for efficient and reproducible *in* 110
vivo testing of enhancer activity. The construct consists of the eGFP expression cassette under 111
the control of the zebrafish E1b minimal promoter (Becker et al., 2016) flanked by Ds elements 112

for integration into the genome (Emelyanov et al., 2006, Emelyanov and Parinov, 2008), and 113
features a multiple cloning site for cloning enhancer sequences to test upstream of the minimal 114
promoter (Fig.1A). We compared the efficiency and efficacy of Ac/Ds- and Tol2-mediated 115
integration (Kawakami, 2004) by transiently expressing a previously predicted zebrafish 116
enhancer for *pax3a* with strong activity (Trinh et al., 2017, Gavriouchkina et al., 2017) (“*pax3a* 117
enhancer”). Ac/Ds and Tol2 versions of the *pax3a* enhancer were microinjected into 118
Gt(FoxD3:mCherry)^{ct110aR} transgenic embryos (Hochgreb-Hägele and Bronner, 2013) together 119
with 24 pg Ac or 50-80 pg Tol2 mRNA, respectively. We observed a clean and tissue-specific 120
pattern of eGFP expression in neural crest cells at the neural plate border with 30 pg of the 121
Ac/Ds vector, a result that could only be recapitulated with 150 pg of Tol2 vector (Fig.1A), 122
indicating higher somatic integration efficiency by Ac/Ds as previously reported (Vrljicak et al., 123
2016). To quantify this observation, we collected embryos injected with 30 pg of the Ac/Ds or 124
Tol2 *pax3a* enhancer for GFP immunohistochemistry (IHC) together with Hoechst-staining of 125
nuclei, followed by confocal imaging and Imaris image analysis (Supp.Fig.1, Materials & 126
Methods). Ac/Ds-injected embryos demonstrated up to 9-fold increase in GFP⁺/Hoechst⁺ 127
signal compared to Tol2-injected embryos (p=0.001) (Fig.1B). The lower load requirement for 128
Ac/Ds (30 pg per embryo) to yield efficient integration also resulted in much lower mosaicity 129
within a clutch of injected embryos (64 to 95% of injected embryos with distinguishable 130
expression pattern, compared to <40% for Tol2) and therefore provided an efficient binary 131
yes/no tool for transient screening of enhancer activity. To assess the limitations of 132
Ac/Ds-integration in F₀, we next compared Ac/Ds and Tol2 versions of a previously predicted 133
enhancer for *sox10* with weak activity (scattered labelling of few neural crest cells with either 134
method) (Trinh et al., 2017, Gavriouchkina et al., 2017) (“*sox10* enhancer”) using the same 135
quantification approach (Supp.Fig.2). Tol2-injected embryos demonstrated more mosaic 136
intra-clutch GFP expression pattern compared to Ac/Ds-injected embryos, with a higher 137
proportion of embryos without any specific detectable GFP⁺ cells that were excluded from 138
quantification. Conversely, although weak “*sox10* enhancer” showed smaller number of GFP⁺ 139
cells per embryo, Ac/Ds-integration approach allowed us to detect reproducible and consistent 140
neural crest-specific activity of this enhancer. While Ac/Ds- and Tol2-mediated integration of 141

the ‘weak’ enhancer resulted in comparable GFP⁺/Hoechst⁺ signal, a much higher variability 142
between embryos was observed by the Tol2-mediated approach (Fig.1C). 143

These results demonstrated a clear advantage of Ac/Ds- over Tol2-mediated enhancer testing, 144
and in general transient expression systems using DNA constructs in zebrafish, as Ac/Ds 145
transposition yielded a higher number of construct integrations resulting in lower cell mosaicity 146
rate. This was particularly notable with a strong element such as the *pax3a* enhancer, where a 147
high number of cells showing consistent enhancer activity pattern were successfully labelled. 148
Furthermore, the utility of Ac/Ds in being able to inject both DNA and mRNA at lower 149
amounts is significant. Toxicity issues associated with the higher levels required for Tol2-based 150
somatic integration could be avoided, and lower amounts of DNA required for high integration 151
efficiency minimises ectopic activity from episomal expression of non-integrated plasmid. This 152
places the zebrafish embryo on par with the chick embryo as an excellent model for testing 153
enhancer activity transiently in injected F₀ embryos (Streit et al., 2013). Taken together, we 154
demonstrated that Ac/Ds-mediated integration is not only more efficient for transgenes with 155
strong activity but at the same time more efficacious for transgenes with weaker activity. 156



157

Figure 1. Ac/Ds integration is more effective than Tol2 in F₀ embryos.

A Schematic of constructs containing a neural crest *pax3a* enhancer (cyan) positioned upstream of the zebrafish E1b minimal promoter (grey) and driving eGFP (green) expression harbouring either Ds- or Tol2-integration arms (black). 30 pg of either construct (“Ac/Ds” and “Tol2”) was microinjected into *Gt(FoxD3:mCherry)^{ct110aR}* embryos (to visualise neural tube) together with Ac or Tol2 mRNA, respectively. Live confocal imaging highlighted similar levels of neural crest cell labelling between 30 pg Ac/Ds and 150 pg Tol2, but 30 pg Tol2 injections yielded much weaker signal in comparison. **B** Labelling efficiencies of the Ac/Ds and Tol2 *pax3a* enhancer were quantified using immunohistochemistry and Imaris. Ac/Ds resulted in up to 9-fold increase (Student *t*-test; $p=0.001$) of GFP⁺/Hoechst⁺ signal compared to Tol2. **C** The same approach in (**B**) was used to compare labelling efficiency of a *sox10* enhancer with weak activity. Although both versions resulted in comparable GFP⁺/Hoechst⁺ signal, Ac/Ds demonstrated less variability compared to Tol2. Scale bar: 40 μ m.

***In vivo* characterisation of novel neural crest enhancers using Ac/Ds.**

Having established the utility of Ac/Ds for testing enhancers in F₀ embryos, we further characterised the *pax3a* and *sox10* enhancers described earlier following germline transmission (Fig.2, *pax3a*_E5 and *sox10*_E2). We found that germline transmission rates for Ac/Ds-injected embryos were comparable to Tol2, consistent with previous reports (Emelyanov et al., 2006, Emelyanov and Parinov, 2008). We also characterised three additional enhancers - one predicted for *pax3a* and two for *sox10* (Fig.2; *pax3a*_E4, *sox10*_E5 and E7) in both F₀ and following germline transmission (*pax3a*_E4), or in F₀ only (*sox10*_E5 and E7) (Supp.Fig.3). *Pax3a* and *sox10* are well-characterised transcription factors with known roles in neural crest development (Alkobtawi et al., 2018). *Pax3a*_E4 and E5 are located 23.5 and 6kb upstream of the transcription start site (TSS) of *pax3a* at open chromatin regions detected by ATAC-seq (Buenrostro et al., 2013) performed on FAC-sorted neural crest cells (Trinh et al., 2017, Gavriouchkina et al., 2017) (Fig.2A, maroon track). *Sox10*_E2, E5 and E7 are located 33, 13kb upstream of the TSS and 3.7kb downstream of the 3'UTR of *sox10*, respectively (Fig.2B, maroon track).


To test the co-localisation of *pax3a* expression with *pax3a*_E4 or *pax3a*_E5 activity, we utilised the Hybridisation Chain Reaction (HCR) method (Choi et al., 2018) to detect *eGFP* and endogenous *pax3a* mRNAs. At 6 somite stage (ss), *pax3a* is strongly expressed in premigratory neural crest at the neural plate border region (Fig.2A, cartoon reproduced from Zfin *in situ* data). Co-localisation of *eGFP* and *pax3a* mRNA transcripts in this region were detected in F₀-injected embryos, and this result was recapitulated in F₂ embryos, *Tg(pax3a_enh5-E1b:eGFP)^{ox163}* (Fig.2A). *Pax3a*_E4 gave a similar result but with overall weaker eGFP expression in both F₀ and F₂, *Tg(pax3a_enh4-E1b:eGFP)^{ox162}* (Supp.Fig.3).

Next, we tested the co-localisation of Sox10 expression with *sox10*_E2, E5 and E7 activity using immunohistochemistry to detect eGFP and endogenous Sox10 proteins. At 18 ss, *sox10* is strongly expressed in migratory neural crest within the cranial region (Fig.2B, cartoon reproduced from (Gavriouchkina et al., 2017)). All *sox10* enhancers demonstrated weak but Sox10-specific activity in F₀-injected embryos (Fig.2B, Supp.Fig.3). Remarkably,

*sox10*_E2-driven eGFP expression dramatically improved following germline transmission with a much higher number of GFP⁺/Sox10⁺ cells being detected in *Tg(sox10_enh2-E1b:eGFP)^{ox120}* F₂ embryos (Fig.2B). Interestingly, this “germline-boosting” effect was not observed in five other enhancer lines that we have propagated to the germline.

To recover integration sites of the transgene in a genome-wide fashion, we performed splinkerette-PCR-NGS on a pool of GFP⁺ F₂ embryos (Supp.Fig.4, Materials & Methods). High-confidence sites were defined as genomic regions where the signal of mapped reads from splinkerette PCR amplicons representing genomic regions flanking Ds-5' and 3' arms were enriched over background (qval<0.01) (Fig.2B', splink Rv and splink Fwd tracks). We identified 3,521 high-confidence sites, significantly higher than a previous study reporting 1,685 integration sites across 424 Ac/Ds transgenic lines (Vrljicak et al., 2016). We reasoned that our result may represent most of the initial integration events still present in the F₁ germline, as indicated by the 5,473 putative inserts identified in F₀-injected embryos by Vrljicak *et al.*. Echoing the previous study, we also found a large proportion of integration sites (88.2%) to overlap annotated repeat elements (Fig.2B', pie chart) and enriched at gene regions with broad distribution across promoters, introns, exons and transcription termination sites (TTS) (Fig.2B', red and purple bar chart) (Vrljicak et al., 2016).

The results demonstrated by the weak *sox10*_E2 enhancer fortuitously highlighted the potential for our approach to uncover candidates that would otherwise have been overlooked at the F₀ screening stage if Tol2-integration was used. The higher likelihood of a false positive result with Tol2 could influence a negative decision for the propagation of the transgene as a reporter line, thus eliminating potential lines that could be biologically relevant. In short, we showed that the Ac/Ds enhancer construct is a robust and useful tool to characterise putative enhancers with both strong and weak activity.



210

Figure 2. *In vivo* characterisation of *pax3a* and *sox10* enhancers using Ac/Ds integration. Full legend on next page.

A Two putative *pax3a* enhancers (E4 and E5; E5 also shown in Fig1) are visualised on UCSC Genome Browser (maroon, ATAC-seq track; indigo, *pax3a* gene locus). E5-driven eGFP transcripts in F₀ and F₂ embryos demonstrated a similar expression pattern that overlapped endogenous *pax3a* mRNA. Note the post-fixing eGFP protein signal detected in F₀ embryo. **B** Three putative *sox10* enhancers (E2, E5 and E7; E2 also shown in Fig1) are visualised on UCSC Genome Browser (maroon, ATAC-seq track; indigo, *sox10* gene locus). EGFP and endogenous Sox10 proteins were detected using immunohistochemistry. Weak E2-driven eGFP activity labelled very few Sox10-positive cells in F₀ embryos. F₂ embryos demonstrated a remarkably higher number of Sox10-positive cells with eGFP activity. **B'** Integration sites of the *sox10*_E2:eGFP transgene in F₂ embryos identified using splinkerette-PCR-NGS. Reads corresponding to flanking genomic regions on Ds-3' end (navy blue; splink Fwd) and Ds-5' end (navy blue; splink Rv) were mapped to the zebrafish genome (GRCz10) and peaks corresponding to integration sites were bioinformatically called (navy blue boxes). The *sox10* locus is shown as an example, with the position of *sox10*_E2 highlighted in orange. 88.2% of integration sites partially/fully overlapped annotated repeat elements (blue; highlighted with dotted box), while the remaining 11.8% (red; highlighted with dotted box) did not. Annotated introns, promoters and exons were enriched ($p < 0.04$) within all integration sites (purple bar chart). Transcription termination sites (TTS) were also enriched ($p < 0.01$) within integration sites that did not overlap annotated repeat elements (red bar chart). Scale bar: 20 μ m; 40 μ m (**B**-stable (F₂)).

Ac/Ds successfully expresses sgRNAs for transient tissue-specific CRISPR*i*.

The ability to knockdown non-coding elements *in vivo* is essential for the dissection of their function. Currently, the most commonly used method to deliver sgRNAs for CRISPR/Cas9 in zebrafish is via microinjection of *in vitro*-transcribed sgRNAs into single cell embryos. While cost-effective and straightforward, this approach risks decreasing the efficiency for CRISPR-mediated events in the embryo, as the uncapped and non-polyadenylated nature of sgRNAs renders them sensitive to degradation *in vivo* (Mir et al., 2018). This is particularly pertinent if the desired goal is to perform CRISPR experiments in a tissue-specific fashion, as unprotected sgRNAs injected in the absence of Cas9 protein or Cas9 mRNA are likely to be diminished by the time a tissue-specific Cas9 protein is expressed many hours later in development.


We took advantage of Ac/Ds to generate a constitutive sgRNA expression system that employs a “transient transgenesis” approach for use in tissue-specific CRISPR/dCas9 (nuclease-deficient Cas9) modulation of targeted non-coding loci and enhancers in F₀ embryos. To express sgRNAs, we cloned a cassette containing a zebrafish-specific U6a promoter driving

expression of sgRNAs (Yin et al., 2015) into a custom-made Ac/Ds mini-vector (Fig.3A, 245
Materials & Methods). The 20bp spacer region within the cassette was flanked by *Bsm*BI 246
restriction sites to facilitate GoldenGate (Clarke et al., 2012)-like cloning of different sgRNAs 247
(Supp.Fig.5A). We compared continuous expression of a scrambled sgRNA sequence from the 248
integrated Ac/Ds-U6a:sgRNA vector (pVC-Ds-DrU6a:sgRNA-Ds) and an *in vitro*-transcribed 249
sgRNA transcript by injecting 50 pg of vector (with 24 pg *Ac* mRNA) or 80 pg of transcript into 250
wild type embryos, followed by RT-PCR at 5 hours post injection (hpi), 24 hpi and 5 days post 251
injection (dpi). We found that sgRNA expression up to 5 dpi could only be detected using 252
Ac/Ds (Fig.3A). To achieve tissue-specific (neural crest) expression of dCas9 fused to repressive 253
effector protein (SID4x) for CRISPR/dCas9-interference (CRISPR*i*) at target regions (Fig.3B), 254
we generated BAC transgenic line *TgBAC(sox10:dCas9-SID4x-2a-Citrine)^{ox117}* (“ox117”) by 255
taking advantage of the previously validated *sox10* BAC clone (Trinh et al., 2017). This 256
approach enabled neural crest-specific expression of dCas9-SID4x in an endogenous *sox10*-like 257
fashion, under the control of regulatory elements embedded within the *sox10* regulatory locus 258
contained in the BAC clone (Fig.3C). 259

We reasoned that the small size of the Ac/Ds-U6a:sgRNA mini-vector (<4.5kb), coupled 260
with the small load required for activity, would permit pooling of multiple sgRNAs. We tested a 261
load of up to 160 pg DNA per embryo, where the survival rate was ~50% in our hands. 262
Multiplexing sgRNAs is crucial for CRISPR*i*, given previous studies demonstrating the 263
requirement for multiple sgRNAs to illicit successful knockdown (Qi et al., 2013, Williams et al., 264
2018). Previous evidence has also highlighted CRISPR*i*'s potential for strand-specific 265
mode-of-action when dCas9 is used to target transcription elongation, but not initiation, using 266
sgRNAs that bind the non-template strand (Qi et al., 2013). To explore this possibility in the 267
zebrafish, we microinjected incrossed ox117 embryos with an Ac/Ds-sgRNA pool containing five 268
sgRNAs that target the TSS of STRG.15268.1, an antisense transcript overlapping *sox9a* 269
 (“*sox9a* lncRNA”), while avoiding targeting of *sox9a* elongation (Supp.Fig.5B). The *sox9a* 270
lncRNA was identified by *de novo* assembly (Pertea et al., 2015) of previously published neural 271
crest RNA-seq datasets (Trinh et al., 2017) and is preceded by a strong ATAC-seq peak at its 5' 272
terminus, indicative of promoter activity (Buenrostro et al., 2013) (Fig.3D, maroon track). 273

A major obstacle to the study of lncRNAs is their significantly lower levels of expression compared to their protein-coding counterparts (Derrien et al., 2012). To circumvent this issue and quantify *sox9a* lncRNA levels following CRISPR*i*, we performed semi-quantitative transcript-specific RT-PCR with *βactin* as endogenous control (Fig.3D). To quantify *sox9a* while taking into account potential strand-unspecific effects, *sox9a* was reverse-transcribed using a gene-specific primer targeted at its 3'UTR and localised upstream of the five sgRNAs targeting the TSS of *sox9a* lncRNA. Transcript levels were measured using qPCR as per standard practice (Fig.3D). We found modest knockdown ($p=0.03$) of *sox9a* lncRNA in the presence of sgRNAs compared to scrambled sgRNAs or uninjected controls (Fig.3D'), while *sox9a* transcript levels were unaffected in the same samples (Fig.3D''). These findings were consistent with our observation that injected embryos were morphologically normal and support recent evidence that lncRNAs were largely dispensable for development (Goudarzi et al., 2018).

In short, we demonstrated that re-purposing of the Ac/Ds approach enabled constitutive expression of sgRNAs in embryos *in vivo* following genomic integration of the construct into somatic cells. By pooling multiple sgRNAs, we also provided proof-of-principle evidence that CRISPR*i* could be achieved in a strand-specific fashion on a locus with overlapping antisense transcription. As an aside, we have also generated modified versions of the Ac/Ds-sgRNA vector containing RNA scaffolds for KRAB transcriptional repression (Zalatan et al., 2015) and for the synergistic transcription activation mediator (SAM) system (Koneremann et al., 2015). The latter can be coupled with the *TgBAC(sox10:Cas9m4-VP64-2a-Citrine)^{ox118}* line we have also generated, to enable for CRISPR/dCas9-activation (CRISPR*a*) of targeted loci (Mali et al., 2013) (Supp.Material).



296

Figure 3. Ac/Ds ubiquitous expression of sgRNAs for Sox10-specific CRISPR*i* in the neural crest of transgenic F₀ embryos. Full legend on next page.

A A zebrafish U6a promoter is used to drive expression of an sgRNA cassette consisting of spacer region (20bp target sequence), tracrRNA and a U6 termination sequence (U6stop). The entire transgene is flanked by Ds integration arms (black). AcDs-U6a:sgRNA was microinjected into incrossed ox117 embryos and its sgRNA transcript detected by RT-PCR (red arrows indicate primers; product size 86bp) at 5 hours post-injection (hpi), 24 hpi and 5 days post-injection (5 dpi). In parallel, embryos microinjected with *in vitro*-transcribed sgRNA (with same sequence as AcDs version) were also accessed. At 5 dpi, sgRNA expression was only detected in embryos microinjected with AcDs-U6a:sgRNA. **B** Nuclease-deficient Cas9 (green; dCas9) fused to the SID4x repressor domain (violet) is targeted to a region-of-interest using sgRNAs (red). The SID4x domain enables transcriptional repression via chromatin compaction, possibly by recruiting histone deacetylases (HDACs). **C** A Sox10-specific CRISPR*i* transgenic line, *TgBAC(sox10:dCas9-SID4x-2a-Citrine)^{ox117}*, was generated using BAC recombination and Tol2-mediated transgenesis. A ribosome-skipping TaV-2a peptide (2a) mediates separation of dCas9-SID4x from its Citrine reporter protein. The transgene successfully labels neural crest (white arrows) and the otic vesicle (ov) *in vivo*. **D** Five AcDs-U6a:sgRNAs targeting the TSS of STRG.15268.1, a transcript overlapping *sox9a* in the opposing strand ("*sox9a* lncRNA"), were microinjected into ox117 incrossed embryos. Strand-specific reverse transcription (RT) was performed using primers that bind specifically to the predicted 3' end of *sox9a* lncRNA (orange) or the 3'UTR of *sox9a* mRNA (indigo). The *sox9a* mRNA RT primer is positioned upstream of *sox9a* lncRNA's TSS target region. In both cases, *βactin* was also primed as an endogenous control. *Sox9a* lncRNA and *sox9a* mRNA were measured using semi-quantitative PCR and qPCR, respectively. **D'** Semi-quantitative PCR revealed a modest knockdown (Student *t*-test; *p*=0.03) of *sox9a* lncRNA in the presence of sgRNAs compared to controls. **D''** *Sox9a* mRNA transcript levels were unaffected by *sox9a* lncRNA CRISPR*i*, indicating a strand-specific mode-of-action. Scale bar: 40 μm.

CRISPR*i* of *sox10* enhancers affects Sox10 expression.

Finally, we investigated the functional relationship between *sox10*_E2, E5 and E7 enhancers, characterised by our Ac/Ds enhancer assay, and endogenous *sox10* expression using our optimised CRISPR*i* approach (Fig.4A), as enhancer effect on gene expression is thought to be additive (Hay et al., 2016, Will et al., 2017). To test the contributions of multiple enhancers to *sox10* gene activity, *TgBAC(sox10:dCas9-SID4x-2a-Citrine)^{ox117}* incrossed embryos were injected with a pool of 15 Ac/Ds sgRNAs targeting all three *sox10* enhancers. Embryos were fixed and immunohistochemistry performed to detect Citrine (cells expressing dCas9-SID4x) and nuclei containing endogenous Sox10 protein (Materials & Methods). We identified three different scenarios in terms of co-expression - (1) dCas9-SID4x⁺ only* cells, (2) *sox10*⁺/dCas-SID4x⁺** double-positive cells and (3) Sox10⁺ only cells (this scenario was observed due to faint levels of Citrine at the stage of analysis) (Fig.4B). We reasoned that such

a combined outcome and scenario (3) with a decrease in Citrine occurred also due to the fact 334
our approach did not only target *sox10*_E2, E5 and E7 enhancers within the endogenous *sox10* 335
locus, but also within the regulatory region included in the ox117 BAC allele driving 336
dCas9-SID4x. As a consequence, Citrine and dCas9-SID4x expression was progressively 337
decreased and with it lessened the effect of epigenome modulation. To quantify this 338
phenomenon, we decided to focus on initial stages dCas9-SID4x activity to avoid the decrease in 339
its activity (and thus release of inhibition) due to the described regulatory conundrum. Three 340
different embryos (+/- Ac/Ds sgRNAs) were subjected to the same immunohistochemistry 341
protocol and imaged; dCas9-SID4x⁺ cells were counted on individual slices [i.e. scenario 342
(1)+(2)] and scenario (2), see Materials & Methods, Supp.Material). The knockdown effect was 343
calculated as a ratio of Sox10⁺/dCas-SID4x⁺** cells in dCas9-SID4x⁺ (* + **) counted cells 344
(Fig.4B'). Similar to the *sox9a* lncRNA knockdown experiment, we showed that deactivating 345
these three enhancers modestly diminished Sox10 expression ($p=0.02$) (Fig.4B'). 346

In conclusion, these results demonstrated the utility of our Ac/Ds approach as an exploratory 347
tool to cell-specifically probe enhancers in order to elucidate their function *in vivo*, without the 348
need for or prior to laborious generation of stable transgenic lines for further characterisation. 349




Figure 4. CRISPR*i* of *sox10* enhancers affects Sox10 expression.

A CRISPR*i* was performed on three *sox10* enhancers described earlier (E2, E5 and E7) by simultaneously microinjecting five AcDs-U6a:sgRNAs per enhancer (15 in total) into ox117 incrossed embryos. Immunohistochemistry followed by confocal imaging to detect Citrine and Sox10 proteins was used as a qualitative and quantitative readout of interference. **B** Two outcomes (*; Sox10 protein undetected and **; Sox10 protein detected) were observed as a result of *sox10*_E2,E5,E7 CRISPR*i* in cells where Citrine (ergo dCas9-SID4x) is present, indicating incomplete knockdown and/or secondary effects of the sgRNAs targeting *sox10*_E2,5,7 that are also present on the dCas9-SID4x BAC allele. **B'** To quantify this observation, cells with high Citrine expression (dCas9-SID4x⁺) were individually counted in two separate slices per embryo across three different embryos per condition. The ratio of Sox10⁺/dCas9-SID4x⁺ events in dCas9-SID4x⁺ counted cells revealed a modest decrease (Student *t*-test; *p*=0.02) in Sox10 expression following *sox10*_E2,E5,E7 CRISPR*i*. Scale bar: 40 μ m (**B**); 20 μ m (**B'**).

Materials & Methods 351

1. Zebrafish husbandry 352

All zebrafish experiments were conducted according to regulated procedures authorised by the 353
UK Home Office within the framework of the Animals (Scientific Procedures) Act 1986. Wild 354
type and transgenic embryos were derived from AB or AB/TL mix strains. 355

2. Plasmids and oligo sequences 356

Full lists of plasmids (including Addgene submissions) and oligo sequences are available as 357
Supplementary Material. 358

3. Enhancer vector cloning 359

Putative enhancer elements were amplified from genomic DNA by PCR and cloned into 360
pVC-Ds-E1b:eGFP-Ds (Addgene ID 102417) linearised with *NheI*. Cloning was performed using 361
In-FusionTM HD Cloning Plus (Takara) or Gibson Assembly cloning (Gibson et al., 2009). 362
Cloning reactions were transformed into chemo-competent cells and plasmids were prepared 363
using QIAprep Spin Miniprep kit (27104, Qiagen) and stored in Elution Buffer. Inserts were 364
verified by Sanger sequencing using T7 primer. 365

4. Cloning of Ac/Ds-U6a:sgRNA vector(s) 366

We previously generated a mini-vector with Ds arms flanking a multiple cloning site 367
(pVC-Ds-MCS-DS; Addgene ID 102416). The insert consisting of zebrafish U6a promoter, 368
spacer region, tracrRNA, and U6 termination sequence (Yin et al., 2015) was amplified by PCR 369
using a custom-ordered gBlock Gene Fragment (Integrated DNA Technologies) as template. 370
The PCR product was gel-purified and cloned into the mini-vector linearised with *SnaBI* and 371
NheI, using In-FusionTM HD Cloning Plus (Takara). To clone desired sgRNA targets, 372
complementary oligo pairs were ordered as follows: (1) TTCG-5'[20bp target without PAM]3' and 373
(2) AAAC-5'[20bp target without PAM in reverse complement]3' (Supp.Material). 50 µM of each 374
oligo were combined in a 50 µL reaction and annealed in a thermocycler (94 °C 5 mins, decrease 375

to 22 °C at 1 °C/min, 4 °C hold). Cloning reaction was prepared by combining 70 ng 376
pVC-Ds-DrU6a:sgRNA-Ds vector, 5 ng annealed sgRNA, 10U of *Bsm*BI and 20U of T4 DNA 377
ligase (M0202, NEB) in 1X T4 DNA Ligase Buffer with final volume 20 µL. ‘GoldenGate’ 378
cycling conditions were used as follows: 10X(37 °C 5 mins, 16 °C 10 min), 50 °C 5 mins, 80 °C 5 379
mins. 2 µL of the reaction was transformed into chemo-competent cells and plated onto 380
Ampicillin plates. Two colonies per sgRNA were screened by Sanger sequencing using U6a 381
promoter primer TCACTCACCACCTCCCAAAA. 382

5. *Ac* transposase mRNA synthesis 383

To prepare *Ac* transposase mRNA, pAC-SP6 (Addgene ID 102418) (Emelyanov et al., 2006) 384
was linearised with *Bam*HI and purified under RNase-free conditions. *In vitro* transcription was 385
performed using mMMESSAGE mMACHINE™ SP6 Transcription Kit (AM1340, ThermoFisher). 386
mRNA was purified under RNase-free conditions using phenol-chloroform followed by ethanol 387
precipitation and the pellet resuspended in RNase-free water. mRNA quality was assessed by 388
gel electrophoresis (sharp intact band without degradation) and quantified using Qubit™ RNA 389
HS Assay kit (Q32852, ThermoFisher). For long term storage in –80 °C the purified mRNA 390
was prepared as 1 µL aliquots and limited to one freeze-thaw cycle. Prior to use, an aliquot is 391
freshly diluted with nuclease-free water and the excess discarded after use. 392

6. *Ac*/*Ds* microinjections 393

All microinjections were performed by injecting 2.3 nL into the blastula of one-cell stage 394
embryos within 5 to 20 mins post fertilisation. To prepare microinjection aliquots, Miniprep 395
plasmids in Elution Buffer were diluted at least 20-fold with nuclease-free water. The following 396
conditions have been optimised using the Nanoject II system (Drummond Scientific) and may 397
have to be adjusted if using a different microinjector. 398

6.1 Enhancer screening. For *Ac*/*Ds* vectors, each embryo was injected with 30 pg of DNA 399
and 24 pg *Ac* mRNA. To compare with *Tol2* vectors, each embryo was injected with 30 pg of 400
DNA and 80 pg *Tol2* mRNA, or 150 pg of DNA and 50 pg *Tol2* mRNA (lethality ~50%). 401

6.2 Ac/Ds-U6a:sgRNA injections for CRISPR*i*. Single sgRNA injections were performed with 50 pg of DNA and 24 pg *Ac* mRNA per embryo. For pooling more than one sgRNA, up to 160 pg of DNA and 24 pg *Ac* mRNA were injected per embryo (maximum 15 different sgRNAs).

7. Ac vs Tol2 quantification

Following eGFP (with Hoechst) immunohistochemistry (see Section 14), dorsal views of embryos were imaged as 50 μm Z-stacks on LSM780 Inverted confocal microscope (Zeiss) using the same laser and acquisition settings throughout. Raw images were rendered on Imaris (Bitplane) as “Spots” and “Surfaces” for Hoechst and GFP channels, respectively. To compute total GFP intensity (x), GFP Mean Intensity values of “Spots” with $d > 0$ (d =distance from Hoechst “Spot” to GFP “Surface”), was summed. GFP intensity per 1 μm^2 “Surface” Area, y , was calculated by dividing x with total “Surface” Area detected. GFP intensity for 50 μm^2 , $y * 50$, was plotted as a bar chart.

8. Ac/Ds-U6a:sgRNA vector vs *in vitro*-transcribed sgRNA RT-PCR

Total RNA was extracted from pools of 11 microinjected embryos per condition (vector, or IVT) using RNAqueous-Micro Total RNA Isolation Kit (AM1931, ThermoFisher). Reverse transcription (RT) was performed using 0.5 μM each of R_sgRNA_scaffold_tail (Supp.Material) in a 10 μL reaction (1 μg starting RNA) using SuperScriptTM III Reverse Transcriptase (18080093, ThermoFisher). Reverse transcription was performed at 55 $^{\circ}\text{C}$ for 60 mins. Primary PCR was performed using the following primers: R_sgRNA and F_scrambled1_spacer (Supp.Material). In a 20 μL reaction, 0.1 μM per primer was combined with 1 μL of template (reverse transcription reaction) in 1X standard *Taq* polymerase PCR reaction. Cycling was performed as follows: 95 $^{\circ}\text{C}$ 5 mins, 35X(95 $^{\circ}\text{C}$ 30s, 55 $^{\circ}\text{C}$ 30s), 68 $^{\circ}\text{C}$ 30s, 12 $^{\circ}\text{C}$ hold. Next, secondary PCR was performed using the following primers: R_nested_sgRNA and F_nested_scrambled1_spacer (Supp.Material). In a 20 μL reaction, 0.1 μM per primer was combined with 1 μL of template (primary PCR reaction) in 1X standard *Taq* polymerase PCR reaction. Cycling was performed as follows: 95 $^{\circ}\text{C}$ 5 mins, 23X(95 $^{\circ}\text{C}$ 30s, 55 $^{\circ}\text{C}$ 30s), 68 $^{\circ}\text{C}$ 30s,

12 °C hold. Results were analysed on a single 2% agarose gel using a 100bp ladder. 429

9. Generation of CRISPR transgenic lines 430

TgBAC(sox10:dCas9-SID4x-2a-Citrine)^{ox117} and *TgBAC(sox10:Cas9m4-VP64-2a-Citrine)^{ox118}* 431
(Mali et al., 2013) were generated using BAC recombination followed by Tol2 transgenesis as 432
previously described (Suster et al., 2011, Trinh et al., 2017). Recombination cassettes were 433
amplified from pGEM-T-Easy-HA-NLS-dCas9-NLS-SID4x-TaV-2a-Citrine-FRT-Kan-FRT and 434
pGEM-T-Easy-HA-NLS-Cas9m4-NLS-VP64-TaV-2a-Citrine-FRT-Kan-FRT (Supp.Material) to 435
introduce 50bp homology arms for recombination into the *sox10* locus in BAC clone 436
DKEY-201F15, by replacing *sox10*'s first exon with the recombination cassette. 437

10. Sox10 quantification following *sox10_E2-7 CRISPRi* 438

Following Sox10 and Citrine immunohistochemistry (see section 14), Z-stack images of the 439
anterior cranial region were obtained using 2.5 µm slices. Two slices (at least 15 µm apart) 440
per embryo were used for analysis. First, cells (or cell clusters) with strongest anti-GFP 441
(Citrine) signal (ergo dCas9-SID4x) were highlighted. Next, the highlighted GFP signal was 442
superimposed onto the Hoechst channel to refine dCas9-SID4x⁺ cell count. Finally, 443
dCas9-SID4x⁺/Hoechst⁺ cells with Sox10 signal were counted. This process was repeated for 444
all slices used in the analysis. 445

11. *sox9a* lncRNA RT-PCR 446

Total RNA was extracted from pools of 10 CRISPR*i*-microinjected embryos per condition 447
(+sgRNAs, +scrambled sgRNAs, -sgRNAs) using RNAqueous-Micro Total RNA Isolation Kit 448
(AM1931, ThermoFisher). *Sox9a* lncRNA-specific reverse transcription (RT) was performed 449
using 0.5 µM each of R_STRG.15268.1, R2_STRG.15268.1 and *bactin_E4_R3* (Supp.Material) in 450
a 10 µL reaction (maximising amount of starting RNA) using SuperScriptTM III Reverse 451
Transcriptase (18080093, ThermoFisher). Reverse transcription was performed at 55 °C for 60 452
mins. *Sox9a* lncRNA and *βactin* PCR were performed using the following primers: 453
R2_STRG.15268.1 and R_sox9aE3; *beta-actin_E3* and *beta-actin_E4* (Supp.Material). In a 20 µL 454

reaction, 0.2 μ M per primer was combined with a 1 μ L of template (1:10 dilution of reverse transcription reaction) in 1X Phusion^R High-Fidelity PCR Master Mix with HF Buffer (M0531, NEB). Cycling was performed as follows: 98 °C 5 mins, 23X(98 °C 30s, 57 °C 30s), 72 °C 30s, 12 °C hold. Results were analysed on a single 1.5% agarose gel using the 100bp band of 1kb or 1kb Plus ladder (NEB) as reference. Relative band intensities to selected reference were quantified using BioRad's Image LabTM Software.

12. *sox9a* qPCR

Both the total RNA extracted for *sox9a* lncRNA RT-PCR as well as the RT protocol were re-utilised for *sox9a*-specific reverse transcription. Instead, RT primer combination used were R_ox9a_3UTR and bactin_E4_R3. QPCR was performed using the $\Delta\Delta$ Ct method with 300 nM of *sox9a* primers (F_ox9a_E2 and R_ox9a_E3) and 150 nM *βactin* primers (beta-actin_E3 and beta-actin_E4) in Fast SYBRTM Green Master Mix (4385612, ThermoFisher). 0.5 μ L of template (1:10 dilution of reverse transcription reaction) was used in a 10 μ L reaction.

13. Splinkerette-PCR-NGS

13.1 Preparation of splinkerette library. To assess a wide spectrum of possible integration sites of the *Ac/Ds sox10* enhancer 2 transgene, Tg(*sox10.enh2-E1b:eGFP*)^{ox120} F1 individuals were outcrossed and 25 GFP⁺ F2 embryos were collected for genomic DNA extraction. As a control, genomic DNA was also extracted from wild type embryos and processed in parallel. 500 ng of genomic DNA was digested with 20U of *AluI* (R0137, NEB) in a 30 μ L reaction at 37 °C in a thermocycler with heated lid for 4 hours. The digest reaction was purified using phenol-chloroform extraction followed by ethanol precipitation and the pellet resuspended with 34 μ L of nuclease-free water. Splinkerette adaptors (SPLINK-top_VC and SPLINK-bottom_VC; Supp.Material) were annealed at 25 μ M final concentration each in 2.5 μ L volume with the following cycling conditions: 95 °C 2 mins, decrease 95 - 22 °C at 0.1 °C/second and ending with 22 °C 5 mins before placing on ice. The ligation reaction was prepared by combining 17 μ L of purified *AluI*-digested genomic DNA with 0.5 μ L annealed adaptors and 10U of T4 DNA ligase (M0202, NEB) in 1X T4 DNA ligase buffer. Ligation was incubated

overnight at 16 °C in a thermocycler with heated lid, subsequently purified using DNA Clean & Concentrator (D4003, Zymo Research) and eluted with 25 µL DNA Elution Buffer. A primary PCR reaction (12.5 µL volume) was setup by combining 10 ng of ligated DNA with 0.25 µL each of 10 µM SPLINK_P1 and DS-3' forward or DS-5' reverse P1 primers (Supp.Material) in 1X Platinum SuperFi master mix (12358010, ThermoFisher). Cycling was performed as follows: 98 °C 2 mins, 25X(98 °C 10s, 63 °C 30s, 72 °C 3 mins), 72 °C 5 mins, 12 °C hold. After cycling, 1 µL of the primary PCR reaction was combined with 1 µL each of 10 µM SPLINK_P2 and DS-3' forward or DS-5' reverse P2 primers (Supp.Material) in 1X Platinum SuperFi master mix (50 µL volume) for secondary PCR. Cycling was performed like primary PCR, with the exception that annealing temperature was lowered to 60 °C. 5 µL of the secondary PCR reaction was run on a 2% agarose gel to assess amplification of genomic regions flanking integrations. Prior to library prep for Next Generation Sequencing (NGS), the secondary PCR reactions were purified using Select-a-Size DNA Clean & Concentrator (D4080, Zymo Research) according to manufacturer's instructions to enrich for amplicons between 100-1000bp. Purified amplicons were quantified by QubitTM dsDNA HS Assay kit (Q32854, ThermoFisher) and 50 ng used as starting input for library prep. Library prep was performed using Nextera DNA Library Prep Kit (FC-121-1030, Illumina) according to manufacturer's instructions and their fragment profiles (~200bp expected) assessed on the TapeStation (Agilent Technologies). Libraries were sequenced on NextSeq500 Illumina platform (v2 150 cycles, 80-bp paired end) to obtain ~4 million reads per forward/reverse sample.

13.2 Bioinformatics analysis. Obtained reads were quality trimmed using sickle (Joshi and Fass, 2011) and -1 30 -q 30 parameters. Trimmed reads were mapped to the *D.rerio* genome (GRCz10) using STAR (Dobin et al., 2013) with default parameters. Book-ended mapped regions on the same strand were merged using bedtools merge (Quinlan and Hall, 2010) to 'recapitulate' amplicon fragments prior to tagmentation during library prep. To identify regions with significant signal over background in mapped reads (10 to 50-fold enrichment, ergo integration sites), peaks were called using MACS2 callpeaks (Zhang et al., 2008) with -g 1.41e9 -m 10 50 --nomodel --shiftsize X -q 0.01 parameters, where X=library

fragment size/2. To filter out ‘high-confidence’ called peaks, bedtools intersect was used to 510
retrieve common peaks found in both forward and reverse samples overlapping by at least 1bp. 511
If desired, peaks that overlapped annotated repeat elements by at least 1bp were removed using 512
bedtools subtract. Genome ontology analysis of peaks were performed using HOMER 513
annotatePeaks.pl (Heinz et al., 2010) with `-genomeOntology` 514
`intersect_positions_genomeOntology -gsize 1.41e9` parameters. 515

14. Whole-mount immunohistochemistry 516

Embryos were fixed in 4% paraformaldehyde (PFA) for 45 minutes at room temperature (RT). 517
After washing, embryos were blocked using 10% goat serum in PBT (PBS, 0.5% Triton, 2% 518
DMSO) for 1 hour at RT. Primary antibodies used were chicken anti-GFP (to detect eGFP or 519
Citrine) (ab13970, Abcam) and rabbit anti-zfSox10 (GTX128374, GeneTex) in a 1:200 dilution, 520
added overnight at 4 °C. Secondary antibodies used were donkey anti-rabbit 568nm (A10042, 521
ThermoFisher) and goat anti-chicken 647nm (A21449, ThermoFisher) in 1:400 dilution each, 522
together with Hoechst reagent (H3569, ThermoFisher) in a 1:1000 dilution to label nuclei - all 523
added for 2 hours at RT. After washing to remove excess, embryos were imaged using a LSM780 524
confocal microscope (Zeiss). 525

15. Hybridisation Chain Reaction 526

Embryos were fixed in 4% paraformaldehyde (PFA) overnight at 4 °C, washed in 527
phosphate-buffered saline (PBS), dehydrated in methanol (MeOH) and stored at -20 °C. 528
Hybridization chain reaction (HCR) v3.0 was performed according to published protocol (Choi 529
et al., 2018). Briefly, embryos were rehydrated with a series of graded MeOH/PBS-Triton 530
(PBST) washes and incubated overnight at 37 °C in 30% probe hybridization buffer containing 531
2 pmol of each probe mixture (pax3a and GFP). Excess probes were washed off with 30% probe 532
wash buffer at 37 °C and 5XSSCT at RT. Embryos were then incubated overnight at RT in 533
amplification buffer containing 15 pmol of each fluorophore-labelled hairpin (B3-546 and 534
B2-488). Excess hairpins were removed by washing with 5XSSCT at RT. Following HCR, 535
embryos were imaged using a LSM780 confocal microscope (Zeiss). 536

Competing interests

537

P.R.R. is co-founder and equity holder in OxStem Cardio. All the other authors declare no competing interests.

538

539

Author contributions

540

Conceptualisation, V.C.-M., T.S.-S.; Methodology, V.C.-M., U.S., F.C.S.; Investigation,

541

V.C.-M., F.C.S., D.S.C.; Writing - Original Draft, V.C.-M.; Writing - Review & Editing, all

542

authors; Supervision, T.S.-S.; Funding Acquisition, T.S.-S., P.R.R.

543

Acknowledgements and funding

544

This work was supported by MRC (G0902418), Lister Institute Research Prize, Oxford BHF

545

CRE award (RE/08/004) to T.S.-S. and (RE/13/1/30181) to F.C.S., RDM Pump Priming

546

Grant (HSD00040) to T.S.-S. and V.C.-M., Clarendon Fund Fellowship to V.C.-M., BHF

547

Programme grant and Chair award (RG/13/9/303269 and CH/11/1/28798) to P.R.R.. We

548

would like to thank Wenbiao Chen for advice on choice of zebrafish U6a promoter, Sarah de Val

549

for E1b minimal promoter cassette, Joey Riepsaame for dCas9-SID4x construct, and current

550

collaborators who have requested the enhancer construct for their work.

551

References

552

Peter Hugo Lodewijk Krijger and Wouter de Laat. Regulation of disease-associated gene

553

expression in the 3D genome. *Nature Reviews Molecular Cell Biology*, 17(12):771–782, 2016.

554

ISSN 14710080. doi: 10.1038/nrm.2016.138.

555

Jesse M. Engreitz, Noah Ollikainen, and Mitchell Guttman. Long non-coding RNAs: spatial

556

amplifiers that control nuclear structure and gene expression. *Nature Reviews Molecular Cell*

557

Biology, 17(12):756–770, 2016. ISSN 1471-0072. doi: 10.1038/nrm.2016.126.

558

- Ryan Rickels and Ali Shilatifard. Enhancer Logic and Mechanics in Development and Disease. 559
Trends in Cell Biology, 28(8):608–630, 2018. ISSN 18793088. doi: 10.1016/j.tcb.2018.04.003. 560
- Jeffrey J. Quinn and Howard Y. Chang. Unique features of long non-coding RNA biogenesis 561
and function. *Nature reviews. Genetics*, 17(1):47–62, 2015. ISSN 1471-0064. doi: 562
10.1038/nrg.2015.10. 563
- Andrew R Bassett, Asifa Akhtar, Denise P Barlow, Adrian P Bird, Neil Brockdorff, Denis 564
Duboule, Anne Ephrussi, Anne C Ferguson-Smith, Thomas R Gingeras, Wilfried Haerty, 565
Douglas R Higgs, Eric a Miska, and Chris P Ponting. Considerations when investigating 566
lncRNA function in vivo. *eLife*, 3:1–14, 8 2014. ISSN 2050-084X. doi: 10.7554/eLife.03058. 567
- Barbara McClintock. The Origin and Behavior of Mutable Loci in Maize. *Genetics*, 36(6): 568
344–355, 1950. ISSN 0027-8424. doi: 10.1073/pnas.36.6.344. 569
- N. Fedoroff, S. Wessler, and M. Shure. Isolation of the transposable maize controlling elements 570
Ac and Ds. *Cell*, 35(1):235–242, 1983. ISSN 00928674. doi: 10.1016/0092-8674(83)90226-X. 571
- Alexander Emelyanov, Yuan Gao, Naweed Isaak Naqvi, and Serguei Parinov. Trans-kingdom 572
transposition of the maize Dissociation element. *Genetics*, 174(3):1095–1104, 2006. ISSN 573
00166731. doi: 10.1534/genetics.106.061184. 574
- Alexander Emelyanov and Serguei Parinov. Mifepristone-inducible LexPR system to drive and 575
control gene expression in transgenic zebrafish. *Developmental Biology*, 320(1):113–121, 2008. 576
ISSN 00121606. doi: 10.1016/j.ydbio.2008.04.042. 577
- A. Kenyon, D. Gavriouchkina, J. Zorman, V. Chong-Morrison, G. Napolitani, V. Cerundolo, 578
and T. Sauka-Spengler. Generation of a double binary transgenic zebrafish model to study 579
myeloid gene regulation in response to oncogene activation in melanocytes. *DMM Disease 580
Models and Mechanisms*, 11(4), 2018. ISSN 17548411. doi: 10.1242/dmm.030056. 581
- Helen Ngoc Bao Quach, Shijie Tao, Pavle Vrljicak, Adita Joshi, Hua Ruan, Rashmi Sukumaran, 582
Gaurav K Varshney, Matthew C LaFave, Shawn M Burgess, Christoph Winkler, Alexander 583
Emelyanov, Sergey Parinov, and Karuna Sampath. A Multifunctional Mutagenesis System 584

- for Analysis of Gene Function in Zebrafish. *G3 (Bethesda, Md.)*, 5(6):1283–99, 2015. ISSN 2160-1836. doi: 10.1534/g3.114.015842. 585
586
- Koichi Kawakami. Tol2: a versatile gene transfer vector in vertebrates. *Genome Biology*, 8 (Suppl 1):S7, 2007. ISSN 14656906. doi: 10.1186/gb-2007-8-s1-s7. 587
588
- Pavle Vrljicak, Shijie Tao, Gaurav K. Varshney, Helen Ngoc Bao Quach, Adita Joshi, Matthew C. LaFave, Shawn M. Burgess, and Karuna Sampath. Genome-Wide Analysis of Transposon and Retroviral Insertions Reveals Preferential Integrations in Regions of DNA Flexibility. *G3: Genes, Genomes, Genetics*, 6(4):805–817, 2016. ISSN 2160-1836. doi: 10.1534/g3.115.026849. 589
590
591
592
593
- Lei S Qi, Matthew H Larson, Luke a Gilbert, Jennifer a Doudna, Jonathan S Weissman, Adam P Arkin, and Wendell a Lim. Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. *Cell*, 152(5):1173–83, 2 2013. ISSN 1097-4172. doi: 10.1016/j.cell.2013.02.022. 594
595
596
597
- Luke A Gilbert, Matthew H Larson, Leonardo Morsut, Zairan Liu, Gloria A Brar, Sandra E Torres, Noam Stern-Ginossar, Onn Brandman, Evan H Whitehead, Jennifer A Doudna, Wendell A Lim, Jonathan S Weissman, and Lei S Qi. CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. *Cell*, 154(2):442–51, 7 2013. ISSN 1097-4172. doi: 10.1016/j.cell.2013.06.044. 598
599
600
601
602
- Silvana Konermann, Mark D Brigham, Alexandro E Trevino, Patrick D Hsu, Matthias Heidenreich, Le Cong, Randall J Platt, David a Scott, George M Church, and Feng Zhang. Optical control of mammalian endogenous transcription and epigenetic states. *Nature*, 500 (7463):472–6, 2013. ISSN 1476-4687. doi: 10.1038/nature12466. 603
604
605
606
- Pratiksha I Thakore, Anthony M, D’Ippolito, Lingyun Song, Alexias Safi, Nishkala K Shivakumar, Ami M Kabadi, Timothy E Reddy, Gregory E Crawford, and Charles A Gersbach. Highly specific epigenome editing by CRISPR-Cas9 repressors for silencing of distal regulatory elements. *Nat Methods*, 12(12):1143–1149, 2015. ISSN 1548-7091. doi: 10.1038/nmeth.3630. 607
608
609
610
611

- Silvana Konermann, Mark D. Brigham, Alexandro E. Trevino, Julia Joung, Omar O. Abudayyeh, Clea Barcena, Patrick D. Hsu, Naomi Habib, Jonathan S. Gootenberg, Hiroshi Nishimasu, Osamu Nureki, and Feng Zhang. Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex. *Nature*, 517(7536):583–8, 2015. ISSN 0028-0836. doi: 10.1038/nature14136.
- S J Liu, S John Liu, Max A Horlbeck, Seung Woo Cho, Harjus S Birk, Martina Malatesta, Frank J Attenello, Jacqueline E Villalta, Min Y Cho, Yuwen Chen, A Mandegar, Michael P Olvera, Luke A Gilbert, Bruce R Conklin, Howard Y Chang, Jonathan S Weissman, and Daniel A Lim. CRISPRi-based genome-scale identification of functional long noncoding RNA loci in human cells. 7111(December), 2016. ISSN 0036-8075. doi: 10.1126/science.aah7111.
- Ruth M Williams, Upeka Senanayake, Mara Artibani, Gunes Taylor, Daniel Wells, Ahmed Ashour Ahmed, and Tatjana Sauka-Spengler. Genome and epigenome engineering CRISPR toolkit for in vivo modulation of cis -regulatory interactions and gene expression in the chicken embryo. *Development*, page dev.160333, 2018. ISSN 0950-1991. doi: 10.1242/dev.160333.
- Prashant Mali, John Aach, P Benjamin Stranges, Kevin M Esvelt, Mark Moosburner, Sriram Kosuri, Luhan Yang, and George M Church. CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering. *Nature biotechnology*, 31(9):833–8, 9 2013. ISSN 1546-1696. doi: 10.1038/nbt.2675.
- Aamir Mir, Julia F. Alterman, Matthew R. Hassler, Alexandre J. Debacker, Edward Hudgens, Dimas Echeverria, Michael H. Brodsky, Anastasia Khvorova, Jonathan K. Watts, and Erik J. Sontheimer. Heavily and fully modified RNAs guide efficient SpyCas9-mediated genome editing. *Nature Communications*, 9(1):1–9, 2018. ISSN 20411723. doi: 10.1038/s41467-018-05073-z.
- Philipp W. Becker, Natalia Sacilotto, Svanhild Nornes, Alice Neal, Max O. Thomas, Ke Liu, Chris Preece, Indrika Ratnayaka, Benjamin Davies, George Bou-Gharios, and Sarah De Val. An intronic Flk1 enhancer directs arterial-specific expression via RBPJ-mediated venous

- repression. *Arteriosclerosis, Thrombosis, and Vascular Biology*, 36(6):1209–1219, 2016. ISSN 15244636. doi: 10.1161/ATVBAHA.116.307517. 639
640
- Koichi Kawakami. Transgenesis and Gene Trap Methods in Zebrafish by Using the Tol2 Transposable Element. *Methods in Cell Biology*, 77:201–222, 2004. ISSN 0091679X. doi: 10.1016/S0091-679X(04)77011-9. 641
642
643
- Le A. Trinh, Vanessa Chong-Morrison, Daria Gavriouchkina, Tatiana Hochgreb-Hägele, Upeka Senanayake, Scott E. Fraser, and Tatjana Sauka-Spengler. Biotagging of Specific Cell Populations in Zebrafish Reveals Gene Regulatory Logic Encoded in the Nuclear Transcriptome. *Cell Reports*, 19(2):425–440, 2017. ISSN 22111247. doi: 10.1016/j.celrep.2017.03.045. 644
645
646
647
648
- Daria Gavriouchkina, Ruth M Williams, Martyna Lukoseviciute, Tatiana Hochgreb-Hägele, Vanessa Chong-Morrison, Supat Thongjuea, Emmanouela Repapi, and Adam Mead. From pioneer to repressor: Bimodal foxd3 activity dynamically remodels neural crest regulatory landscape in vivo. *bioRxiv*, 2017. doi: 10.1101/213611. 649
650
651
652
- Tatiana Hochgreb-Hägele and Marianne E Bronner. A novel FoxD3 gene trap line reveals neural crest precursor movement and a role for FoxD3 in their specification. *Developmental biology*, 374(1):1–11, 2 2013. ISSN 1095-564X. doi: 10.1016/j.ydbio.2012.11.035. 653
654
655
- Andrea Streit, Monica Tambalo, Jingchen Chen, Timothy Grocott, Maryam Anwar, Alona Sosinsky, and Claudio D. Stern. Experimental approaches for gene regulatory network construction: The chick as a model system. *Genesis*, 51(5):296–310, 2013. ISSN 1526954X. doi: 10.1002/dvg.22359. 656
657
658
659
- Mansour Alkobtawi, Heather Ray, Elias H. Barriga, Mauricio Moreno, Ryan Kerney, Anne Helene Monsoro-Burq, Jean Pierre Saint-Jeannet, and Roberto Mayor. Characterization of Pax3 and Sox10 transgenic *Xenopus laevis* embryos as tools to study neural crest development. *Developmental Biology*, (February):1–7, 2018. ISSN 1095564X. doi: 10.1016/j.ydbio.2018.02.020. 660
661
662
663
664

- Jason D Buenrostro, Paul G Giresi, Lisa C Zaba, Howard Y Chang, and William J Greenleaf. 665
Transposition of native chromatin for fast and sensitive epigenomic profiling of open 666
chromatin, DNA-binding proteins and nucleosome position. *Nature methods*, 10(12):1213–8, 667
2013. ISSN 1548-7105. doi: 10.1038/nmeth.2688. 668
- Harry M T Choi, Maayan Schwarzkopf, Mark E Fornace, Aneesh Acharya, Georgios Artavanis, 669
Johannes Stegmaier, Alexandre Cunha, and Niles A Pierce. Third-generation in situ 670
hybridization chain reaction: multiplexed, quantitative, sensitive, versatile, robust. 671
Development, 145(12):dev165753, 2018. ISSN 0950-1991. doi: 10.1242/dev.165753. 672
- Linlin Yin, Lisette A. Maddison, Mingyu Li, Nergis Kara, Matthew C. Lafave, Gaurav K. 673
Varshney, Shawn M. Burgess, James G. Patton, and Wenbiao Chen. Multiplex conditional 674
mutagenesis using transgenic expression of Cas9 and sgRNAs. *Genetics*, 200(2):431–441, 675
2015. ISSN 19432631. doi: 10.1534/genetics.115.176917. 676
- Brian D. Clarke, David M. Cummins, Ken a. McColl, Alister C. Ward, and Tim J. Doran. 677
Characterization of Zebrafish Polymerase III Promoters for the Expression of Short-Hairpin 678
RNA Interference Molecules. *Zebrafish*, 10(4):121002061007008, 2012. ISSN 1545-8547. doi: 679
10.1089/zeb.2012.0782. 680
- Mihaela Pertea, Geo M Pertea, Corina M Antonescu, Tsung-Cheng Chang, Joshua T Mendell, 681
and Steven L Salzberg. StringTie enables improved reconstruction of a transcriptome from 682
RNA-seq reads. *Nature Biotechnology*, 33(3):290–295, 2015. ISSN 1087-0156. doi: 683
10.1038/nbt.3122. 684
- Thomas Derrien, Rory Johnson, Giovanni Bussotti, Andrea Tanzer, Sarah Djebali, Hagen 685
Tilgner, Gregory Guernec, David Martin, Angelika Merkel, David G Knowles, Julien Lagarde, 686
Lavanya Veeravalli, Xiaoan Ruan, Yijun Ruan, Timo Lassmann, Piero Carninci, James B 687
Brown, Leonard Lipovich, Jose M Gonzalez, Mark Thomas, Carrie a Davis, Ramin 688
Shiekhattar, Thomas R Gingeras, Tim J Hubbard, Cedric Notredame, Jennifer Harrow, and 689
Roderic Guigó. The GENCODE v7 catalog of human long noncoding RNAs: analysis of their 690

- gene structure, evolution, and expression. *Genome research*, 22(9):1775–89, 9 2012. ISSN 1549-5469. doi: 10.1101/gr.132159.111. 691
692
- Mehdi Goudarzi, Kathryn Berg, Lindsey M Pieper, and Alexander F Schier. Long non-coding RNAs are largely dispensable for zebrafish embryogenesis, viability and fertility. *bioRxiv*, pages 1–22, 2018. doi: 10.1101/374702. 693
694
695
- Jesse G. Zalatan, Michael E. Lee, Ricardo Almeida, Luke A. Gilbert, Evan H. Whitehead, Marie La Russa, Jordan C. Tsai, Jonathan S. Weissman, John E. Dueber, Lei S. Qi, and Wendell A. Lim. Engineering complex synthetic transcriptional programs with CRISPR RNA scaffolds. *Cell*, 160(1-2):339–350, 2015. ISSN 10974172. doi: 10.1016/j.cell.2014.11.052. 696
697
698
699
- Deborah Hay, Jim R. Hughes, Christian Babbs, James O.J. Davies, Bryony J. Graham, Lars L.P. Hanssen, Mira T. Kassouf, A. Marieke Oudelaar, Jacqueline A. Sharpe, Maria C. Suci, Jelena Telenius, Ruth Williams, Christina Rode, Pik Shan Li, Len A. Pennacchio, Jacqueline A. Sloane-Stanley, Helena Ayyub, Sue Butler, Tatjana Sauka-Spengler, Richard J. Gibbons, Andrew J.H. Smith, William G. Wood, and Douglas R. Higgs. Genetic dissection of the α -globin super-enhancer in vivo. *Nature Genetics*, 48(8):895–903, 2016. ISSN 15461718. doi: 10.1038/ng.3605. 700
701
702
703
704
705
706
- Anja J. Will, Giulia Cova, Marco Osterwalder, Wing Lee Chan, Lars Wittler, Norbert Brieske, Verena Heinrich, Jean Pierre De Villartay, Martin Vingron, Eva Klopocki, Axel Visel, Darío G. Lupianez, and Stefan Mundlos. Composition and dosage of a multipartite enhancer cluster control developmental expression of *Ihh* (Indian hedgehog). *Nature Genetics*, 49(10): 1539–1545, 2017. ISSN 15461718. doi: 10.1038/ng.3939. 707
708
709
710
711
- Daniel G Gibson, Lei Young, Ray-Yuan Chuang, J Craig Venter, Clyde a Hutchison, Hamilton O Smith, Clyde A Hutchison Iii, and Nature America. Enzymatic assembly of DNA molecules up to several hundred kilobases. *Nature Methods*, 6(5):343–345, 2009. ISSN 1548-7105. doi: 10.1038/nmeth.1318. 712
713
714
715
- Maximiliano L Suster, Gembu Abe, Anders Schouw, and Koichi Kawakami. 716

- Transposon-mediated BAC transgenesis in zebrafish. *Nature Protocols*, 6(12):1998–2021, 2011. 717
ISSN 1750-2799. doi: 10.1038/nprot.2011.416. 718
- NA Joshi and JN Fass. Sickle: A sliding-window, adaptive, quality-based trimming tool for 719
FastQ files (Version 1.33), 2011. URL <https://github.com/najoshi/sickle>. 720
- Alexander Dobin, Carrie A. Davis, Felix Schlesinger, Jorg Drenkow, Chris Zaleski, Sonali Jha, 721
Philippe Batut, Mark Chaisson, and Thomas R. Gingeras. STAR: Ultrafast universal 722
RNA-seq aligner. *Bioinformatics*, 29(1):15–21, 2013. ISSN 13674803. doi: 723
10.1093/bioinformatics/bts635. 724
- Aaron R. Quinlan and Ira M. Hall. BEDTools: A flexible suite of utilities for comparing 725
genomic features. *Bioinformatics*, 26(6):841–842, 2010. ISSN 13674803. doi: 726
10.1093/bioinformatics/btq033. 727
- Yong Zhang, Tao Liu, Clifford A. Meyer, Jérôme Eeckhoute, David S. Johnson, Bradley E. 728
Bernstein, Chad Nussbaum, Richard M. Myers, Myles Brown, Wei Li, and X. Shirley Shirley. 729
Model-based analysis of ChIP-Seq (MACS). *Genome Biology*, 9(9), 2008. ISSN 14747596. 730
doi: 10.1186/gb-2008-9-9-r137. 731
- Sven Heinz, Christopher Benner, Nathanael Spann, Eric Bertolino, Yin C. Lin, Peter Laslo, 732
Jason X. Cheng, Cornelis Murre, Harinder Singh, and Christopher K. Glass. Simple 733
Combinations of Lineage-Determining Transcription Factors Prime cis-Regulatory Elements 734
Required for Macrophage and B Cell Identities. *Molecular Cell*, 38(4):576–589, 2010. ISSN 735
10972765. doi: 10.1016/j.molcel.2010.05.004. 736